IHS Chemical Week

People & Business :: Companies

AstraZeneca’s MedImmune Bid Queried

1:46 PM MDT | May 2, 2007 | Chemical Week Editorial Staff

Shareholders at AstraZeneca’s annual meeting last week raised concerns about the firm’s recent $58/share offer to purchase biotechnology firm MedImmune (Gaithersburg, MD). AstraZeneca’s offer values MedImmune at $15.6 billion and represents a 21% premium over MedImmune’s closing share price on April 20, three days before the bid was announced. Shareholders at the meeting questioned whether the proposed deal is “an act of desperation.” AstraZeneca has been hit by a string of drug candidate failures of late and these may have...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa